Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969565 | 0.87 | TACR1 (0.55) | GAAALDH1A1CTSSCTSKTACR1 | |
| SCHEMBL16865569 | 0.85 | CTSL (0.41) | CTSLKMT2AACEALDH1A1LMNA | |
| SCHEMBL10335429 | 0.84 | CTSL (0.51) | CTSLCTSSCTSKCTSB | |
| SCHEMBL5689118 | 0.84 | TACR1 (0.55) | CTSLALDH1A1CTSSCTSKCTSB | |
| SCHEMBL14488100 | 0.84 | TACR1 (0.55) | CTSLALDH1A1CTSSCTSKCTSB | |
| SCHEMBL17039822 | 0.84 | TACR1 (0.55) | CTSLALDH1A1CTSSCTSKCTSB | |
| SCHEMBL31633412 | 0.84 | CTSC (0.46) | KMT2AALDH1A1LMNATACR1 | |
| SCHEMBL2615853 | 0.83 | TACR1 (0.46) | CTSLGAARAB9AALDH1A1LMNA | |
| SCHEMBL30233807 | 0.83 | OPRK1 (0.48) | ALDH1A1TACR1 | |
| SCHEMBL16167854 | 0.82 | CTSL (0.39) | CTSLKMT2AACEALDH1A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-10-16 | — | — | US | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
| US-4707490-A | AMINO ACID ESTERS OF THIOPROPANOYL-3,4-DEHYDROPROLINE | UNIVERSITY OF MIAMI (US) | 1987-11-17 | — | — | US | disclosed |
| US-4695582-A | Inhibitors of angiotensin converting enzyme | UNIVERSITY OF MIAMI (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0009898-B1 | NOVEL ANTI-HYPERTENSIVE MERCAPTOACYLAMINO ACID DERIVATIVES, THEIR PREPARATION AND USE | UNIVERSITY OF MIAMI (US) | 1983-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | CTSL 58/4885KMT2A 906/4885ACE 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.